HEALTHLEAD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.3 THB | -0.96% |
|
-1.90% | -0.96% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 33.23 times its estimated earnings per share for the ongoing year.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Drug Retailers
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -0.96% | 76.09M | - | ||
| -45.65% | 8.72B | B | ||
| -26.18% | 6.55B | B | ||
| -7.49% | 6.05B | C+ | ||
| +83.84% | 4.84B | C | ||
| -3.80% | 4.57B | D- | ||
| -23.25% | 4.27B | C | ||
| +2.39% | 4.3B | B | ||
| -18.65% | 2.59B | C- | ||
| -12.92% | 2.53B | B |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- HL Stock
- Ratings Healthlead
